Skip to main content

Tarsus Pharmaceuticals, Inc.

corporate_fare Company Profile

Tarsus Pharmaceuticals, Inc.

TARS·NASDAQ·Life Sciences·CIK 0001819790

The company is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutics, primarily in eye care. In August 2023, the company launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, previously known as TP-03, for treating Demodex blepharitis, following U.S. Food and Drug Administration (FDA) approval in July 2023. Demodex blepharitis is an eyelid inflammation caused by Demodex mite infestation, characterized by redness, ocular irritation, and eyelash dandruff called collarettes. This condition can lead to corneal damage and, in extreme cases, blindness. Approximately 25 million people in the U.S. may suffer from Demodex blepharitis. XDEMVY is the first and only FDA-approved therapeutic for this condition, targeting and eradicating Demodex mite infestation. Its active pharmaceutical ingredient, lotilaner, paralyzes and eradicates mites and other parasites by inhibiting parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels, without inhibiting human GABA-Cl. The company has completed seven clinical trials for XDEMVY in Demodex blepharitis, including a Phase 3 trial (Saturn-2), a Phase 2b/3 trial (Saturn-1), four Phase 2 trials, and a Phase 1 trial (Hyperion), all of which met their primary, secondary, and/or certain exploratory endpoints. Additionally, clinical trials in Demodex blepharitis patients with Meibomian Gland Disease (MGD) have been completed, including a Phase 2a clinical trial (Ersa) and a pilot clinical trial (Rhea) involving an XDEMVY vehicle. The company plans to advance its pipeline using the lotilaner API to address various diseases in human medicine, including eye care and infectious disease prevention.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for TARS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 8/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 18 rated 8 or above. Recent SEC coverage for TARS spans 10-Q, 8-K/A, 8-K, 10-K.

Recent high-impact activity:

  • Tarsus 10-Q: Q3 XDEMVY Sales $194.6M, $668.3M Net Loss on $632.2M IPR&D Charge
  • XDEMVY Sales Jump 64% to $194.6M, but $632M IPR&D Charge Drives $668M Quarterly Loss
  • Tarsus Files Alkeus Financials: $564.8M IPR&D Charge and Going Concern Flag
  • Tarsus Closes $450M Alkeus Acquisition, Adds Phase 3 Stargardt Asset
  • Tarsus Q2 2026: XDEMVY Sales Surge 69% to $174M, Operating Cash Flow Turns Positive, and $125M PIPE Priced at $56

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$451.36M
Net Income
-$66.42M
Diluted EPS
-$1.59
Op. Cash Flow
-$12.45M
Free Cash Flow
-$22.31M
Operating Income
-$70.97M
Cash & Equivalents
$183.64M
Total Debt
$72.44M
Debt / Equity
0.21×
Net Margin
-14.7%
Shares Outstanding
42.55M sh
Source: 10-K · filed 2026-02-23 · accession 0001819790-26-000019

Short Interest & Short Volume

6.94 days to cover

FINRA reported short interest of 6,066,524 shares in TARS as of the October 30, 2026 settlement, a 5.9% increase from the prior period — about 6.9 days to cover at its recent average daily volume. On November 20, 2026, 60.7% of TARS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,066,524 shares as of October 30, 2026
Change vs prior period▲ 5.9%
Days to cover6.94 at avg daily volume of 874,486
Daily short volume (FINRA facilities)60.7% of 183,926 shares on November 20, 2026
5-day average short volume57.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for TARS, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.

2 shelf registrations

$125M PIPE Priced at $56.00 · Strategic Investor Participation

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with T →
$71 -2.75% today
52-week range · as of 2026-11-03 $53.89 – $91.53
Market cap
$3.6B
Volume
706.8K (0.7× avg)
3-mo avg 965.3K
Live data · 2026-11-21 06:58 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TARS - Latest Insights

TARS
Nov 03, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $74.00
Real-time Price: $71.00 info
Change: -$3.00 (-4%) info
Market Cap: $3.6B info
TARS
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $71.24
Real-time Price: $71.00 info
Change: -$0.240 (-0.34%) info
Market Cap: $3.6B info
TARS
Oct 13, 2026, 4:00 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $70.82
Real-time Price: $71.00 info
Change: +$0.180 (+0.25%) info
Market Cap: $3.6B info
TARS
Sep 10, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $81.12
Real-time Price: $71.00 info
Change: -$10.12 (-12%) info
Market Cap: $3.6B info
TARS
Aug 06, 2026, 7:25 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $58.27
Real-time Price: $71.00 info
Change: +$12.73 (+22%) info
Market Cap: $3.6B info
TARS
Aug 06, 2026, 7:23 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $58.27
Real-time Price: $71.00 info
Change: +$12.73 (+22%) info
Market Cap: $3.6B info
TARS
Aug 06, 2026, 7:11 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $58.13
Real-time Price: $71.00 info
Change: +$12.87 (+22%) info
Market Cap: $3.6B info
TARS
Aug 06, 2026, 7:08 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $58.50
Real-time Price: $71.00 info
Change: +$12.50 (+21%) info
Market Cap: $3.6B info
TARS
Aug 06, 2026, 7:03 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $58.56
Real-time Price: $71.00 info
Change: +$12.44 (+21%) info
Market Cap: $3.6B info
TARS
Jul 08, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $67.73
Real-time Price: $71.00 info
Change: +$3.27 (+5%) info
Market Cap: $3.6B info
TARS
Jul 08, 2026, 4:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $67.73
Real-time Price: $71.00 info
Change: +$3.27 (+5%) info
Market Cap: $3.6B info
TARS
May 06, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $63.68
Real-time Price: $71.00 info
Change: +$7.32 (+11%) info
Market Cap: $3.6B info
TARS
May 06, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $61.50
Real-time Price: $71.00 info
Change: +$9.50 (+15%) info
Market Cap: $3.6B info
TARS
Mar 31, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $66.92
Real-time Price: $71.00 info
Change: +$4.08 (+6%) info
Market Cap: $3.6B info
TARS
Mar 23, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $64.49
Real-time Price: $71.00 info
Change: +$6.51 (+10%) info
Market Cap: $3.6B info
TARS
Feb 23, 2026, 4:11 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $69.18
Real-time Price: $71.00 info
Change: +$1.82 (+3%) info
Market Cap: $3.6B info
TARS
Feb 23, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $69.18
Real-time Price: $71.00 info
Change: +$1.82 (+3%) info
Market Cap: $3.6B info
TARS
Feb 18, 2026, 8:32 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $62.78
Real-time Price: $71.00 info
Change: +$8.22 (+13%) info
Market Cap: $3.6B info
TARS
Jan 12, 2026, 8:41 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $76.02
Real-time Price: $71.00 info
Change: -$5.02 (-7%) info
Market Cap: $3.6B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets